^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

JBH492

i
Other names: JBH492, JBH-492, JBH 492
Company:
Novartis
Drug class:
Microtubule inhibitor, CCR7-targeted antibody-drug conjugate
Related drugs:
2ms
Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL (clinicaltrials.gov)
P1, N=25, Terminated, Novartis Pharmaceuticals | Active, not recruiting --> Terminated; Business, strategic, and development considerations and not due to any safety concerns
Trial termination
|
JBH492
10ms
Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL (clinicaltrials.gov)
P1, N=25, Active, not recruiting, Novartis Pharmaceuticals | Trial primary completion date: Mar 2024 --> Sep 2024
Trial primary completion date
|
JBH492
1year
Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL (clinicaltrials.gov)
P1, N=25, Active, not recruiting, Novartis Pharmaceuticals | Trial primary completion date: Aug 2024 --> Mar 2024
Trial primary completion date
|
JBH492
1year
Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL (clinicaltrials.gov)
P1, N=25, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Mar 2024 --> Aug 2024 | Trial primary completion date: Mar 2024 --> Aug 2024
Trial completion date • Trial primary completion date
|
JBH492
over1year
Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL (clinicaltrials.gov)
P1, N=25, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting | N=120 --> 25 | Trial completion date: Aug 2024 --> Mar 2024 | Trial primary completion date: Aug 2024 --> Mar 2024
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
|
JBH492